Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pixantrone confers radiosensitization in KRAS mutated cancer cells by suppression of radiation-induced prosurvival pathways.

Free radical biology & medicine - 1 Sept 2022

Tripathi Pragya, Soni Ravi, Antra, Tandon Vibha

Abstract excerpt

Radioresistance towards radiation therapy has generated the need for the development of radiosensitizers as a potential drug. KRAS mutation brings radioresistance in tumor cells. The present work proves sensitization of cancer cells towards radiotherapy through inhibition of KRAS activation. Acquiring a drug repurposing approach, the in-silico screening revealed that pixantrone, an antineoplastic drug, possesses...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Isoquinolines
Share to Lung Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Proteins p21(ras)

Share to Radiation-Sensitizing Agents

Source

Identifiers

PMID: 35970251
DOI: 10.1016/j.freeradbiomed.2022.08.015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pixantrone confers radiosensitization in KRAS mutated cancer cells by suppression of radiation-induced prosurvival pathways.PMID 35970251Read ↗

Prochlorperazine enhances radiosensitivity of non-small cell lung carcinoma by stabilizing GDP-bound mutant KRAS conformation.Semantic proximity Read ↗

Targeting K-Ras-mediated DNA damage response in radiation oncology: Current status, challenges and future perspectivesSemantic proximity Read ↗

Molecularly targeting the PI3K-Akt-mTOR pathway can sensitize cancer cells to radiotherapy and chemotherapySemantic proximity Read ↗

Radiosensitization of Glioblastoma by the K-ras Inhibitor RMC-6236Semantic proximity Read ↗

Triple Blockade of Oncogenic RAS Signaling Using KRAS and MEK Inhibitors in Combination with Irradiation in Pancreatic Cancer.Semantic proximity Read ↗

KZ02 enhances the radiosensitivity of BRAF-mutated CRC in vitro and in vivo.Semantic proximity Read ↗

Clinical target promiscuity: lessons from ras molecular trials.Semantic proximity Read ↗

YB-1 activating cascades as potential targets in KRAS-mutated tumors.Semantic proximity Read ↗

The PI3K/AKT/mTOR signaling pathway inhibitors enhance radiosensitivity in cancer cell linesSemantic proximity Read ↗

Oncogenic KRAS drives radioresistance through upregulation of NRF2-53BP1-mediated non-homologous end-joining repair.Semantic proximity Read ↗

The Influence of Oncogenic RAS on Chemotherapy and Radiotherapy Resistance Through DNA Repair PathwaysSemantic proximity Read ↗

Radio-sensitization of mutated KRAS G12C non-small cell lung cancer with KRAS G12C tyrosine kinase inhibitor and Carbon ions irradiationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.